168 related articles for article (PubMed ID: 10402722)
21. A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer.
Gilani MM; Karimi Zarchi M; Ghaemmaghami F; Behtash N; Mousavi AS; Ansaripoor S
Gynecol Oncol; 2007 Jun; 105(3):780-3. PubMed ID: 17433423
[TBL] [Abstract][Full Text] [Related]
22. Preoperative CA-125 level as a predictor of non optimal cytoreduction of advanced epithelial ovarian cancer.
Gemer O; Segal S; Kopmar A
Acta Obstet Gynecol Scand; 2001 Jun; 80(6):583-5. PubMed ID: 11380298
[TBL] [Abstract][Full Text] [Related]
23. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression.
Simon I; Katsaros D; Rigault de la Longrais I; Massobrio M; Scorilas A; Kim NW; Sarno MJ; Wolfert RL; Diamandis EP
Gynecol Oncol; 2007 Aug; 106(2):334-41. PubMed ID: 17498784
[TBL] [Abstract][Full Text] [Related]
24. [The CA-125 tumor marker in epithelial ovarian cancers of stage I].
Nagele F; Vavra N; Kurz C; Sevelda P
Wien Klin Wochenschr; 1993; 105(20):585-8. PubMed ID: 8259686
[TBL] [Abstract][Full Text] [Related]
25. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
[TBL] [Abstract][Full Text] [Related]
26. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
27. COX-2 and preoperative CA-125 level are strongly correlated with survival and clinical responsiveness to chemotherapy in ovarian cancer.
Raspollini MR; Amunni G; Villanucci A; Boddi V; Taddei GL
Acta Obstet Gynecol Scand; 2006; 85(4):493-8. PubMed ID: 16612714
[TBL] [Abstract][Full Text] [Related]
28. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
[TBL] [Abstract][Full Text] [Related]
29. Pre-operative prediction of serum CA125 level in women with ovarian masses.
Benjapibal M; Neungton C
J Med Assoc Thai; 2007 Oct; 90(10):1986-91. PubMed ID: 18041413
[TBL] [Abstract][Full Text] [Related]
30. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis.
Luo LY; Katsaros D; Scorilas A; Fracchioli S; Bellino R; van Gramberen M; de Bruijn H; Henrik A; Stenman UH; Massobrio M; van der Zee AG; Vergote I; Diamandis EP
Cancer Res; 2003 Feb; 63(4):807-11. PubMed ID: 12591730
[TBL] [Abstract][Full Text] [Related]
31. Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer.
Camlica H; Duranyildiz D; Tas F; Yasasever V
Am J Clin Oncol; 2008 Dec; 31(6):585-8. PubMed ID: 19060592
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of elevated preoperative serum CA125 in ovarian tumors of low malignant potential: a multinational collaborative study (ANZGOG0801).
Tang A; Kondalsamy-Chennakesavan S; Ngan H; Zusterzeel P; Quinn M; Carter J; Leung Y; Obermair A
Gynecol Oncol; 2012 Jul; 126(1):36-40. PubMed ID: 22370601
[TBL] [Abstract][Full Text] [Related]
33. Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study.
Paramasivam S; Tripcony L; Crandon A; Quinn M; Hammond I; Marsden D; Proietto A; Davy M; Carter J; Nicklin J; Perrin L; Obermair A
J Clin Oncol; 2005 Sep; 23(25):5938-42. PubMed ID: 16087942
[TBL] [Abstract][Full Text] [Related]
34. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
[TBL] [Abstract][Full Text] [Related]
35. [Correlation of preoperative serum vascular endothelial growth factor level with CA125 level in patients with epithelial ovarian cancer and its prognostic value].
Tan XJ; Lang JH; Shen K; Wang L; Wu M; Xu XY
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):9-12. PubMed ID: 18366924
[TBL] [Abstract][Full Text] [Related]
36. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
37. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma.
Chi DS; Venkatraman ES; Masson V; Hoskins WJ
Gynecol Oncol; 2000 May; 77(2):227-31. PubMed ID: 10785469
[TBL] [Abstract][Full Text] [Related]
38. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
Moore RG; Brown AK; Miller MC; Skates S; Allard WJ; Verch T; Steinhoff M; Messerlian G; DiSilvestro P; Granai CO; Bast RC
Gynecol Oncol; 2008 Feb; 108(2):402-8. PubMed ID: 18061248
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of CA 125 and TPS levels after chemotherapy in ovarian cancer patients.
van Dalen A; Favier J; Baumgartner L; Hasholzner U; de Bruijn H; Dobbler D; Dombi VH; Fink D; Giai M; McGing P; Harlozinska A; Kainz C; Markowska J; Molina R; Sturgeon C; Einarsson R
Anticancer Res; 1999; 19(4A):2523-6. PubMed ID: 10470187
[TBL] [Abstract][Full Text] [Related]
40. Serial determinations of aminoterminal propeptide of type III procollagen (PIIINP) and prognosis in ovarian cancer; comparison to CA125.
Simojoki M; Santala M; Risteli J; Risteli L; Kauppila A
Anticancer Res; 2000; 20(6C):4655-60. PubMed ID: 11205196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
